Cerebrospinal fluid (CSF) shunting is the gold standard treatment for hydrocephalus in current practices. While numerous lives are saved and quality of life is improved by the simple procedure, it is not without complications. Overdrainage of CSF is one of the most notorious complications after ventriculoperitoneal (VP) shunt implantation. It may result in postural headaches, subdural hematomas (SDH)/hygromas, stenosis/occlusion of the cerebral...
aqueduct, secondary craniostenosis, slit-like ventricles/ slit ventricle syndrome (SVS), and proximal catheter obstruction, etc [1]. The reported incidences of overdrainage range from 2% to 71% due to different study populations, follow-up duration, and definitions of overdrainage [2–10]. The true incidence of overdrainage remains unknown. The Dutch Normal-Pressure Hydrocephalus Study reported subdural effusions of up to 71% in patients with a low pressure shunt [7]. Oi et al. reported slit-like ventricles in about 90% (9/10) of premature neonates (up to 36 weeks gestation) [11]. Overdrainage results from vasogenic and postural effects. In normal subjects, vasogenic effect refers to the intermittent intracranial pressure (ICP) increases related to nocturnal vasogenic events usually triggered by rapid-eye movement (REM) sleep, and CSF is shifted to the spinal subarachnoid spaces [12]. In shunted patients, the nocturnal vasogenic events and diurnal postural effect result in the shifting of CSF into the peritoneal cavity instead of maintaining them inside the subarachnoid spaces.

Siphoning is the phenomenon where fluid continuously flows through an inverted U-shaped tube connecting two containers positioned at different heights. The fluid is “sucked” from the compartment with higher potential energy, flowing upwards against gravity to the “crown” of the system, and finally into the lower compartment. The flow continues until the hydrostatic pressure reaches equilibrium. The traditional theory consisting of Pascal’s principle and Stevin’s law, and the novel molecular cohesion theory provide the physical basis of the siphon effect [13]. Studies on siphon utilize the Bernoulli equation as a theoretical model. The VP shunt connects the intracranial and intra-abdominal compartments, technically becoming a siphon when the system is in the vertical.

Since the 1970s, efforts have been made to overcome the postural drainage effects. Note that postural effect is the main, but not the only contributor to overdrainage. “Antisiphon”, or more universally correct, “overdrainage-preventing” devices are accessories connected in tandem distal to the main valves that work with various mechanisms. To date, there is no perfect overdrainage-preventing product. In this review, we refer to all devices acting as an overdrainage-preventing device with the term antisiphon device (ASD) to avoid confusion. The basics of siphoning, the mechanisms and physical properties of currently available devices are described in this article. The clinical application and considerations are also discussed. This study aims to provide a useful reference for clinical practice of hydrocephalus.

**Physiologic CSF dynamics**

CSF is secreted with an average rate about 0.35 ml/min according to the literature. However, the actual rate may vary greatly depending on the age (0.007–0.45 ml/min in hydrocephalic children of 5–13 years old) and circadian rhythm (e.g. REM sleep) [14,15]. To maintain equilibrium ICPs, the absorption rate of CSF is obviously equal to its production in normal circumstances. In case of suddenly elevated ICP, such as coughing, crying, and vasogenic dilatation of cerebral vessels, the immense absorption reserve up to 100–200 ml/h comes into function [14]. CSF absorption involves the transdural and parenchymal routes. Arachnoid villi are believed to play a major role in transdural absorption. This type of absorption occurs passively under a CSF-dural sinus pressure gradient beginning from 20 to 50 mmH2O [16]. In 2012, Nedergaarda et al. discovered the glymphatic system where there is convective fluid fluxes into and through the brain parenchyma with the CSF and interstitial fluid continuously interchanging [17]. CSF enters the Virchow-Robin space and is subsequently transported into the dense parenchyma by AQP4 water channels expressed on the astrocytic vascular endfeet. It has been shown that the glymphatic system is turned on during sleep and dramatically suppressed during wakefulness [18]. This parenchymal route of CSF absorption also contributes to the secretion of CSF other than the choroid plexus. The equilibrium ICP may be described with Davson’s equation: \( I_{\text{CP}} = R_{\text{out}} I_{\text{form}} + P_{\text{dural}} \), where \( R_{\text{out}} \) is the CSF outflow resistance, \( I_{\text{form}} \) is the CSF formation rate, and \( P_{\text{dural}} \) is the pressure in the dural venous sinuses [18].

The “normal” ICP ranges are 10 ± 5 cmH2O in supine position and 0 ± 5 cmH2O in the upright position, respectively. An overly simplified theory would argue that since the vertical distance between the external auditory canal and the top of the peritoneal cavity is approximately 50–70 cm, the expected ICP drop from supine to upright position would be about 50 cmH2O. It is proven otherwise in reality. Cardiovascular studies suggest that a venous hydrostatic indifference point exist and is located around the top of the diaphragm. In the upright position, the venous pressure above this point is decreased, and those below this point is increased. The pressure of this hydrostatic indifference point is constant no matter what position the subject is in. The model of Magnaes postulates that there is also a hydrostatic indifference point in the CSF axis, and it is located somewhere between C6 and T5 [19]. However, it was shown that this hypothesis only applies in horizontal and vertical positions. In tilt angles in between, this model overestimates the ICP [20]. In vivo studies have shown ICP difference of only about 10 cmH2O in supine and upright positions [21]. This phenomenon is attributed to the collapse of internal jugular vein (IJV) in the upright position [22]. The reference point of the hydrostatic water column is in fact the collapsed segment of IJV, which is about 10–11 cm below the tragus. This perfectly explains the moderate drop of ICP measured in human studies in vertical position. The collapsed IJV works as a Starling resistor. In vertical position, the lumen is nearly, but not totally occluded, and the venous blood flow flutters and passes through intermittently. The flow is no longer dependent of the differential pressure (DP) between the cranial vault and the venous hydrostatic indifference point, but rather dependent of the rate of blood inflow to the upstream segment. The IJVs function as natural ASDs.

**Shunted CSF dynamics**

The presence of a VP shunt effectively bypasses the transdural route of CSF absorption by providing a relatively low resistance pathway, especially in patients with increased CSF outflow resistances. The flow in this pathway is determined...
by the perfusion pressure (PP) or the DP across the valve. If the PP is positive, then flow occurs. PP can be determined with the following equation: \( PP = ICP + HP - (OP or CP + IAP) \), where HP indicates hydrostatic pressure, OP the opening pressure of the valve, CP the closing pressure of the valve, and IAP the intra-abdominal pressure. As shown in Fig. 1 [24], HP can be calculated as \( \rho gh \), where \( \rho \) is the fluid density, \( g \) the gravitational constant (9.8 m/s), and \( h \) the vertical height of the fluid column. In a valve that is normally open, it is expressed with the CP [25]. It has been demonstrated that CP can be as low as 30 cmH2O in the upright position in shunted patients [21,26]. ICP is maintained at –7 to 3 cmH2O in those with an ASD implemented [26]. As the distal compartment, the increase of IAP means a corresponding decrease in PP of the shunt. Posture and activity also significantly influence IAP, such as sitting (16.7 mmHg), standing (20 mmHg), coughing (107 mmHg), and jumping (171 mmHg) [31]. The raises of IAP in sitting and standing postures contribute to the suppression of the very negative ICP measured in shunted patients. ICP in these patients would be ~40 to ~50 cmH2O if IAP had not been elevated when sitting or standing.

The flow through the shunt system is determined on the DP: \( Q = \Delta P / R \), where \( Q \) is the flow, \( \Delta P \) is the DP across the system, and \( R \) is the total resistance of the system. The total resistance is the sum of the resistance of the individual components that make up the system, which at least includes a proximal catheter, a valve, and a distal catheter in most shunt assembly nowadays [14]. The resistance of the catheter can make up a large proportion of the total. The law of Hagen–Poiseuille states, 

\[
Q = \Delta P \times \left( \frac{\pi r^4}{8L} \right)
\]

the flow is proportional to the fourth power of the inner radius \( r \) of the rigid tube, and is inversely related to the viscosity \( \eta \) of the fluid and the length \( L \) of the tube [32]. Common tubes with an internal diameter between 1.1–1.3 mm can drain through 100 cm length with \( \Delta P \) of 30 cmH2O with flow rates of 344 ml/h and 556 ml/h, respectively. This property is beneficial in intermittent ICP crises; however ΔP easily exceeds this value in the erect posture, which leads to detrimental outflow of CSF. Internal diameter of >0.8 mm supports overdrainage [14]. The addition of an ASD increases the total resistance further even in horizontal position, though it may be subtle depending on the design.

**Mechanisms of ASDs**

There are three kinds of ASD design, diaphragm, gravity, and flow reducing devices (Table 1).

**Diaphragm devices (aka membrane-controlled devices)**

A diaphragm device consists of one or two pressure sensitive membranes located at the upstream of the distal catheter. In 1973, Portnoy and Schulte first described the design of an anti-siphon valve [Fig. 2] [33]. The diaphragm is normally displaced from the crown seat as long as the inlet pressure, which is the ICP, is higher than atmospheric pressure, allowing CSF to flow through. When the outlet pressure drops below atmospheric pressure, resulting from the suction effect of the distal water column, the diaphragm is pulled towards the crown seat, closing the water channel. The proximal force (= ICP) required to overcome the siphon effect (= vertical length of the distal water column) is proportional to the ratio of inlet and outlet of the diaphragm device. Thus, the outlet pressure ratio of 8:1, and the distal water column being 80 cm, it would require an ICP of more than 10 cmH2O (= 80/8) to keep the diaphragm chamber open. This hydrodynamic leverage is an application of Pascal’s principle. It was formerly distributed by Integra NeuroSciences with the name Anti-Siphon Device until 2017, when Natus Medical acquired this asset (Natus Medical, Pleasanton, CA, USA). The Siphon Control Device (SCD, aka Delta chamber) (Medtronic PS Medical, Inc., Goleta, California, USA) has a similar design except it consists of a pair of diaphragm instead, with a larger inlet area and a smaller outlet area [Fig. 3]. It is normally closed, and opens only when the proximal pressure is greater than atmospheric pressure, unlike the Anti-Siphon Device (Natus Medical, Pleasanton, CA, USA), which is normally open. In a real subject, however, the subcutaneous pressure (5–9 cmH2O) is needed to be overcome, instead of atmospheric.

Fig. 1 Schematic illustration of the pressures involved in a ventriculoperitoneal shunt. HP = hydrostatic pressure; ICP = intracranial pressure; IAP = intra-abdominal pressure; OP or CP = opening pressure; CP = closing pressure; PP = perfusion pressure. Arrows indicate the direction of force with which the fluid tends to flow. Since ICP is negative in the upright position, it tends to reduce the perfusion pressure, hence the upward arrow.
The hydrodynamic leverage ratio is about 20:1, which theoretically leads to about 1.2 e 2.5 cmH2O increase in OP when the device turns vertical. Note that a diaphragm device distal to the main valve decouples the valve opening from the IAP and negative HP column. Thus the only driving force is the ICP instead of the sum of ICP and HP [35]. Medtronic distributes Strata II (with the SCD), Delta Valve (with the SCD), and Strata NSC (without the SCD).

**Comments**

1. The ability of the diaphragm device to counteract siphon effect depends on the vertical length of the distal hanging water column. This is automatically adjusted in growing children, since the distal catheter is gradually pulled out from the peritoneal cavity along with increasing body height [14]. Some authors proposed that many children are not tall enough to generate sufficient negative hydrostatic pressure to keep the membranes closed [36,37]. However, this statement has not been clinically proven.

2. The ideal location of the diaphragm device seems to be at the level of mastoid process, or approximately 10 cm below the level of the foramen of Monro. This results in physiologic ICP (0–10 cmH2O) and optimal flow initiation in erect positions [34,38]. Placement of the device below this level may lead to overdrainage, and vice versa. In some iNPH patients, however, deliberately implanting the diaphragm device at the clavicle or upper thoracic level may be considered for the goal of lowering the ICP [34,35].

3. The conceptual resemblance to the collapsible IJVs may sound appealing. However, the IJV is present on both sides, and avoids most compressions by the protruding head and shoulders in the lateral decubitus position. The diaphragm device is susceptible to external pressure from the subcutaneous tissue. Although an offset ring is implemented at the circumference of the diaphragm, avoiding direct compression from the scalp, studies have shown significant reduced flow and increased closing pressure of the valve as the external pressure increases [34]. During sleep, the head could be rotated such that the diaphragm is compressed between the skull and the underlying bed. This could lead to functional occlusion of the device and underdrainage [14]. The diaphragm device is best placed in the loose subgaleal space, instead of the neck, chest or abdomen. Subcutaneous implantation causes capsule formation and is likely to result in increased resistance to flow [39].

4. As mentioned above, a positive inlet pressure (i.e. ICP) is required to open the diaphragm device. Since the shunted ICP in the erect posture is negative, it virtually prevents all flow until CSF accumulates and the ICP increases above the OP [35].

5. Studies have shown an increase of 3–6 cmH2O in inlet pressure with DP valves (DPVs) assembled with a diaphragm device compared to DPVs only in the supine position. This works as if the DPV is upgraded in the pressure setting. Thus, it is suggested that the diaphragm device be assembled with a DPV of low pressure setting, instead of a medium or high one [40].

6. With a simulated CSF production rate of 20 ml/h, the diaphragm device effectively reverses the negative inlet pressure of about –50 cmH2O from the siphon to a positive inlet pressure of 12–21.5 cmH2O with in-line low-pressure DPVs. The results were 17–25.4 cmH2O with medium-pressure, and 19.8 to 37 cmH2O with high-pressure DPVs [40].
Gravitational devices (aka ball-in-cone devices and g-valves)

This type of device involves one or several metal spheres contained in a titanium cylinder with a cone shaped seat [Fig. 4]. The middle column of the water channel is with an inverted direction. In horizontal position, the metal balls roll away from the inlet, allowing CSF passage. When the device turns vertical, the metal balls seat on the cone. Thus adding additional pressure ($\Delta P$) depending on the weight of the balls against the entering flow of CSF. The pressure setting of the gravitational device does not affect the OP at all in horizontal position. In combined valves, the OP in vertical position is the sum of the DP unit and the gravitational unit. Theoretically, the relationship of the added OP ($\Delta P$) and the angle ($\alpha$) of the device with respect to horizontal may be expressed with the following equation:

$$\Delta P(\alpha) = \Delta P(90)\sin\alpha, \text{ if } 0^\circ \leq \alpha \leq 180^\circ; \quad \Delta P(\alpha) = 0, \quad -180^\circ < \alpha < 0^\circ \quad [41].$$

Examples of gravitational devices are Gravity Compensating Accessory (GCA, Natus Medical, Pleasanton, CA, USA), Miethke ShuntAssistant (Aesculap, AG, Tuttlingen, Germany) (comes in six ranges, 10 (Paedi-ShuntAssistant), 15, 20, 25, 30,

Fig. 3 Schematic illustration of the Delta chamber, a kind of diaphragm device. The silicone membranes are normally closed. They are displaced from the crown seat when the inlet pressure overcomes the external pressure. The external pressure in a real patient is the tissue pressure of loose subgaleal space or the subcutaneous space, which is slightly higher than the atmospheric pressure. When the device is in vertical position, the negative hydrostatic pressure of the distal water column pulls the diaphragms towards the crown seat, keeping them closed. The area ratio of the inlet area and outlet area is 20:1. Note the slightly higher ring surrounding the diaphragm. It is supposed to prevent some of the direct external pressure (Image adopted from Medtronic Delta® Chamber Instructions for Use, https://www.medtronic.com/).

Fig. 4 Schematic illustration of the ShuntAssistant, a kind of gravitational device. (A) Device in the horizontal position. (B) Device in vertical position, closed. (C) Device in vertical position, open. The device consists of a titanium casing, a tantalum ball, and a sapphire ball. The weight of the tantalum ball provides the additional opening pressure in vertical position. When the differential pressure does not overcome the weight of the tantalum ball, the sapphire ball seats in the ball seat, preventing cerebrospinal fluid flow (Image adopted from Christoph Miethke paedShuntAssistant/ShuntAssistant sales brochure, https://www.aesculapusa.com/).
35 cmH2O), and Siphon X (Sophysa, Orsay, France). The ShuntAssistant is available as a single valve or incorporated with a main DPV (GAV, PaediGAV, ProGAV, ProGAV 2.0, and M.blue). A programmable version of the ShuntAssistant, ProSA, also became available on the market. The pressure setting of combined DP and g-valves is referenced as follows (cmH2O): OP of horizontal position/OP of vertical position. Other examples of gravitational valves (instead of accessories distal to OP of horizontal position/OP of vertical position. Other examples of gravitational valves (instead of accessories distal to the main valve) include Chhabra Z-flow valve (G. Surgiwear Limited, India) and Miethke Dual Switch Valve (Aesculap, AG, Tuttlingen, Germany).

### Supplementary Table 1

A quick reference based on the suggestion of the manufacturer and reports from the literature [36,44]. It is however not a strict rule and should be tailored individually. Note that a typical person is sitting or standing in about 2/3 of the time in a day [35,45]. The effect of the additional OP only takes place in about the same proportion. When following up a patient with a neuroimaging study, the size of the ventricles only represent the net effect of the g-valve with 2/3 of the time being vertical and 1/3 of the time being horizontal. The physical condition and activity should be taken into consideration when choosing the appropriate setting of a g-valve. Most importantly, a g-valve may not fit the needs of a growing child who has changes of physical activity. An adjustable g-valve or pressure-valve may be considered in the growing children.

### Flow reducing devices (aka “flow regulated”, “flow regulating”, “auto-regulating”, “flow controlled”, “low flow”, and “variable-resistance” devices) [14]

These terms may be seen in the literature or on commercial brochures. Whatever term used, this type of device aims to reduce the flow depending on the DP instead of postural changes, thus technically not an “antisiphon” device. This mechanism is often discussed together with true antisiphon devices because they share a common goal of preventing overdrainage. The SiphonGuard (Codman & Shurtleff, Inc., Raynham, Massachusetts, USA) consists of two CSF pathways: a large caliber primary pathway at the center (mean resistance 1.5 mmHg/ml/min), and a spiral secondary pathway surrounding it (mean resistance 42 mmHg/ml/min) [Fig. 7] [46]. The spiral channel is 40 mm long with a diameter of 0.4 mm. This secondary pathway is always open [14]. A ruby ball sits between two opposing springs in the primary pathway. During normal flow, the ball is balanced off the seat, allowing CSF to enter the primary pathway with lower resistance. In the case of excessive flow, the ball seats and blocks the primary pathway, forcing CSF to flow through the secondary pathway with higher resistances, resulting in a low flow state. The DP required to achieve a CSF flow of 0.3 ml/min would be

---

**Fig. 5** Schematic drawing of the direction of inclination (the angle between the axis of the gravitational device and the head). (A) Vertical. (B) Posterior inclination. (C) Anterior inclination. FHP: Frankfort horizontal plane; VL: vertical line. Note that in the case of posterior inclination, the tantalum and sapphire balls roll away from the ball seat when the patient is supine. In the case of anterior inclination, the balls roll onto the ball seat in the supine patient, adding pressure to the cerebrospinal fluid pathway (Image of the device design is adopted from Christoph Miethke paediShuntAssistant/ShuntAssistant Instructions for Use, https://www.aesculapusa.com/).
Fig. 6 Shift of pressure curve depending on the inclination (the angle between the axis of the gravitational device and the head). The given pressure setting of the differential pressure (DP) unit is 5 cmH₂O, and the setting of the gravitational unit (GU) is 20 cmH₂O. Anterior inclination (positive degrees) leads to left shift of the pressure curve, and posterior inclination leads to right shift. An anterior inclination of 30° results in an actual opening pressure (OP) of 15 cmH₂O when the patient lies supine, leading to underdrainage. Anterior inclination also results in undesired low OP when the patient is upright with the head flexed (95° to 135°), leading to overdrainage. Note that an anterior inclination of only 10° results in an OP of 8.47 cmH₂O instead of 5 cmH₂O in supine position. Posterior inclination (negative degrees), on the other hand, doesn’t affect the draining function significantly as shown in the diagram. It could even be beneficial in certain circumstances.

Fig. 7 Schematic illustration of the SiphonGuard, a flow-reducing device. The ball and spring mechanism is encased in a polyethersulfone shell, making it impervious to scar tissue encapsulation or external pressures (Image adopted from CODMAN® SIPHONGUARD® brochure, https://www.integralife.com/).
0.45 mmHg and 12.6 mmHg, in low- and high-flow states, respectively [46]. Examples of flow reducing devices include SiphonGuard (Codman & Shurtleff, Inc., Raynham, Massachusetts, USA), Orbis-Sigma OSV II valve (Integra LifeSciences, Plainsboro, NJ, USA), CRx Diamond valve (Phoenix Biomedical Corp., Valley Forge, PA). The latter two are generally classified as “valves” with integrated flow reducing function instead of an antisiphon device per se. A “valve” is a mechanism that regulates flow and opens when DP exceeds OP. The Orbis-Sigma valve and the CRx Diamond valve (also a slit valve) are multistage flow-regulating valves with their own unique flow–pressure curves. Their opening pressures are about 5 mmHg [47,48]. They are able to function as independent valves in the VP shunt system and usually not implemented in tandem with other valves. SiphonGuard, on the other hand, has virtually no opening pressure. It is utilized as an accessory in tandem with a main valve [46]. The flow–pressure curves of the OSV II and SiphonGuard are presented in [Fig. 8].

### Comments

1. The most distinct feature of this group is that it does not sense body posture. Its function is not “anti-siphon” by nature, but generally flow reducing and not counteracting siphon effect. This mechanism is the only one that is able to reduce excessive CSF flow caused by nocturnal vasogenic events. In another sense, it cannot differentiate standing up from an ICP crisis [14]. Laboratory studies show large hysteresis in flow reducing devices. Wide variations in flow–pressure curves are observed [14,35]. This may be due to the very narrow passageways in this type of devices.

2. It is demonstrated that the SiphonGuard shifts to the low flow state when flow exceeds 1.39 ± 0.42 mL/min (= 83.4 ± 25.2 mL/h), or when ΔP exceeds 15–17 cmH2O [35]. Aschoff's laboratory demonstrated flow peaks of up to 160 mL/h or as low as 50 mL/h before shifting to the low flow state, suggesting a large discrepancy in performance between individual products. In the range of 8–15 cmH2O, the valve permits non-physiologic high flows (>20 mL/h), which may not be a significant problem since the ΔP well exceeds this value when in vertical [14]. Laboratory studies show large hysteresis in flow reducing devices. Wide variations in flow–pressure curves are observed [14,35]. This may be due to the very narrow passageways in this type of devices.

3. In those with slit ventricles, there may not be enough CSF to produce flow above the threshold of state switching. Shorter patients, obese patients, or those who rest persistently in a semisitting position, the drainage rate of 1–1.5 ml/min may cause overdrainage while not activating the flow reducing function. The threshold for switching back to low flow state is below 4–6 mm Hg. In a patient with relatively high ICP, the device may not switch back to high flow state when the subject lies down. The device is thus “locked” in the low flow state and continues to drain CSF with a sub-physiologic rate, resulting in underdrainage [35,46].

4. In contrast with the OSV, the SiphonGuard does not provide a safety stage for drainage in higher ICP circumstances. The OSV on the other hand, may permit excessive drainage and thus non-physiologic low ICP in the upright position, since the hydrostatic pressure easily exceeds the 300 mmH2O threshold.

5. Despite the aforementioned concerns, the SiphonGuard showed relatively stable flow and physiologic ICP compared to the Delta chamber and ProSA in studies using a test bench simulating physiologic situations [35,45].

6. The housings of OSV and SiphonGuard prevent influences from scar tissue encapsulation or external pressure. They can be placed at any level (unlike diaphragm devices) and require no particular orientation (unlike gravitational devices) [37].

---

**Fig. 8** Flow–pressure curves of (A) OSV II and (B) SiphonGuard. There are three stages in OSV II. DP: differential pressure; F: flow. (A) When DP is about 40–120 mmH2O, Stage I begins and the flow rate will be between 5 and 18 ml/h. Stage II begins when the DP is between 120 and 300 mmH2O. The valve operates as a variable-resistance flow regulator, and the flow is restricted between 18 and 30 ml/h. Stage III is the pressure relief mode. It takes place when DP rises above 300 mmH2O, allowing rapid flow rate. This design enables management of postural and vasogenic ICP changes. (B) The SiphonGuard is always patent and the concept of opening pressure does not apply. The resistance is different however, when the primary pathway is open or closed (Image adopted from OSV II brochure and Codman Siphonguard FAQ, https://www.integralife.com).
Clinical efficacy of ASDs in shunt-induced overdrainage conditions

Overdrainage rate

All currently available ASDs have been proven to be able to counteract the negative suction pressure of siphoning to some extent. The definition of overdrainage varies greatly in the literature and results should be interpreted carefully. The determination of superiority of one device over another is difficult owing to the paucity of in vivo comparison in the literature. In a randomized multicenter control trial (SVASONA) in iNPH population, ProGAV, a kind of g-valve was shown to be superior to programmable DPVs in terms of cumulative overdrainage rates (5% and 39% at 6 months, 12% and 59% at 12 months, respectively). It also demonstrated less underdrainage rates at 12 months (2% and 14%, respectively). The Short-Form 12 health survey (SF-12) Mental Component Scores was significantly better at 6- and 12-month clinical visits [9]. An observational study with pediatric and young adult population who suffered from clinical and/or radiological overdrainage treated with adjustable gravitational valve ProSA reported 91% symptom-free at 1 year follow-up [49]. A prospective multicenter study (PRO-SAIKA) reported an overdrainage rate (SDH/SD effusion on neuroimaging studies in patients with symptoms) of 7.9% in adult patients who underwent primary or secondary implantation of ProSA [50]. The authors stated that the somewhat negative patient selection (2/3 were revisions) and imaging in only symptomatic patients resulted in the seemingly higher rate of overdrainage. Other clinical studies regarding g-valves reported overdrainage rates ranging from 0% to 9%, with the exception of one report with 15.6 and another with 21% [9,50–60]. Underdrainage rates ranged from 1.8% to 10.6%, with one exception of 40%. Many studies support the use of a g-valve for overdrainage control [9,49,50,53–58,61,62]. Most studies regarding a diaphragm device date earlier than those regarding g-valves. Outcomes vary among studies. Kondagase et al. reported resolution of severe overdrainage symptoms (19/24 (79.2%) pre-treatment and 1/24 (4.17%) at one year post-treatment) in pediatric population with mixed hydrocephalic etiologies treated with secondary implantation of a programmable valve with diaphragm SCD (Strata valve). The rate of radiologic slit ventricles seemed similar before and after treatment [63]. A prospective cohort study reported less underdrainage rates in the siphon control (Delta valve) group than simple DPV (PS Medical Medium pressure) group [64]. However, there are also studies reported no significant differences in overdrainage rates between SC and NSC [65–67]. Clinical reports regarding the efficacy of SiphonGuard is lacking. Nearly all studies regarding SiphonGuard were laboratory studies [Supplementary Table 2].

Subdural (SD) collections: SD hematomas (SDH)/hygromas

The SVASONA study demonstrated less subdural effusions in the g-valve group than the programmable DPV group (6% and 36%, respectively) [9]. A retrospective chart review with adult population of mixed etiologies concluded that there was no difference in the rate of SDH between siphon control and nonsiphon control groups (4% and 6%, respectively). The valve type was not specified [67].

Slit ventricle syndrome (SVS)/proximal catheter obstruction

This condition is typically observed in older hydrocephalic children who are shunted in infancy [68]. The addition of or replacement to an ASD or a programmable valve is the most popular and reasonable method for treatment. The secondary or primary placement of a diaphragm ASD have shown a dramatic reduction in the incidence of SVS and ventricular catheter obstruction. Better intellectual outcomes are also observed [69]. G-valves have been shown to be able to reduce the rate of proximal obstruction (43%–66%) in pediatric population [61], and also slit ventricles (75% radiological improvement at 1 year) in pediatric and young adults [49].

Shunt survival

Reports on shunt survival regarding ASDs should be interpreted carefully because the valve and catheters also play a role in the system. Other factors such as young age [70], etiology of hydrocephalus [71], entry point [1], shorter interval of revision since the primary shunting, number of revisions [72], and complexity of the assembly also have negative effects on shunt survival [73]. Populations vary among studies. Most studies either did not have a control group or the control group was DPVs instead of another type of ASD. G-valves generally perform well in this respect. One year survival ranges from 53% to 90% [49–52,54,56,57,59,62,74,75]. One year survival of diaphragm devices was about 54%–70% [10,64,65,76–78]. One year survival of the OSV was about 61%–71% [10,76,79,80]. Clinical study regarding the survival of SiphonGuard is lacking. Many studies reported similar shunt survival in the antisiphon group and the DPV group [10,64,65,73,76,81]. However, proximal obstruction may be reduced in shunts with ASDs [49,61,62,69,81] [Supplementary Table 3].

Discussion

Knowing the basics of physiologic and shunted CSF dynamics, the siphon, and the mechanisms and physical properties of currently available ASDs, three questions emerge. First, should an ASD be implemented in all primary shunts? Second, may ASD play a role in the management of overdrainage induced by shunting? Third, what is the role of programmable valves in the management of overdrainage?

A survey was conducted to evaluate the understanding and management preferences among the members of American Society of Pediatric Neurosurgeons. As the choice for primary shunt valve, 41% chose DPVs, 29% DPV + ASD, 27% programmable valves, and 3% OSV. As for the treatment for chronic shunt overdrainage, 45% of members reported often or always placing an ASD, 41% adjusting valve settings, 30% replacing the valve, and less than 20% considered adding an additional valve or shunt assistant. Valve preference was reported as
follows: 50% programmable valve ± ASD, 25% DPV + ASD, 19% OSV, and 3% DPV [82]. Although outcomes have been encouraging in pediatric population, reports showed the contrary argue that the placement of an ASD may result in underdrainage and subsequent alarming neurologic symptoms. This included pediatric patients [61,69,83,84]. Bedridden patients most likely benefit from a DPV only. It is not necessary to place an ASD. Integration of a g-valve has been shown to be harmful in this population [41,43]. Some patients with poor brain compliance may actually need siphoning to achieve adequate treatment effects [85]. As a general guideline, ambulatory patients (older children and most NPH adults) may most likely benefit from the decreased overdrainage rates by implementing an ASD in the shunt configuration. On the contrary, bedridden patients and those with poor consciousness do not need an ASD. Clinical considerations of each type of ASD are summarized in Table 2.

Secondary implantation of an ASD onto the pre-existing shunt has been proven to be effective with the treatment of shunt-induced overdrainage symptoms, SD collections, and slit ventricles [49,50,57,62,69]. It should be considered as long as no contraindications exist.

The Dutch Normal-Pressure Hydrocephalus Study showed that low-pressure valves lead to better neurological outcomes than medium pressure valves, but low-pressure valve were associated with 3.3-times higher relative risk of SD effusions [7]. Programmable valves have been widely used especially in iNPH patients since the 1990s. The 2005 iNPH guidelines stated that they can manage over- and under-drainage noninvasively instead of surgical revisions [86]. Symptoms and signs of overdrainage may resolve by adjusting the valve to a higher pressure setting. However, the treatment effect of CSF diversion is reduced. Studies comparing g-valves and programmable valves without anti-siphon function showed better clinical outcomes in the former group. Improvement in gait imbalance is observed in both groups, but only the g-valve group showed improvement in cognition and bladder functions. The presence of the gravitational unit allows a low pressure setting of the DPV, which leads to better outcome [9,58,87,88]. The hydrostatic pressure in vertical position is larger than the OP of the valve even with the highest pressure setting (200 mmH2O in Codman Hakim Programmable Valve) [89]. In horizontal position, the patient may suffer from under-drainage with high OP. Theoretically, a higher pressure setting to prevent overdrainage is by no means physiologic. Programmable valves are actually DPVs with fixed, but adjustable OP. The original theory of Hakim advocating an adjustable valve uses the function to correct mechanical mismatching due to continuously shrinking ventricle sizes after the initial implant of a shunt. A higher pressure setting is needed to maintain the SD stress after the sizes of ventricles decrease. The ventricles collapse if the intraventricular expansive force (= CSF pressure x ventricular area) is insufficient [90]. Viscosity of CSF may change by time due to degradation of blood products and protein. CSF production rate increases in growing children. The function of programmable valve should be used to fine-tune the OP to match the required IVP according to the aforementioned factors, but not to counteract the siphon effect [89].

---

**Table 1 List of some of the available ASDs on the market.**

| Product                        | Combination valves                                                                 | Manufacturer/Distributor                                  | Mechanism        |
|-------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------|------------------|
| SiphonGuard                   | - Codman Hakim Precision Fixed Pressure Valve with SiphonGuard (In-Line, Right Angle)   | Integra LifeSciences, Plainsboro, NJ, USA                  | Flow reducing    |
|                               | - Codman Hakim programmable valve with SiphonGuard (In-Line, Right Angle)           |                                                          |                  |
|                               | - Codman Hakim programmable valve Lumbo-Peritoneal (L-P) with SiphonGuard (In-Line) |                                                          |                  |
|                               | - Codman Certas Plus Programmable Valve with SiphonGuard (In-Line)                 |                                                          |                  |
| Siphon Control Device         | Strata II, Delta valve                                                             | Medtronic PS Medical, Inc., Goleta, California, USA       | Diaphragm        |
| (SCD, Delta chamber)          |                                                                                   | Natus Medical, Pleasanton, CA, USA                       |                  |
| Anti-Siphon Device (ASD)⁵     | Pudenz Valve, Multi-Purpose Valve, Novus Valve GAV, PaedIGAV, ProGAV, ProGAV 2.0, M.blue | Manufacturer: Christoph Miethke GmbH & Co. KG, Potsdam, Germany Distributor: Aesculap, AG, Tuttlingen, Germany | Diaphragm        |
| Miethke ShuntAssistant, ProSA |                                                                                   | Natus Medical, Pleasanton, CA, USA                        | Gravitational    |
| Gravity Compensating Accessory (GCA)⁵ | Horizontal-Vertical (H–V) Lumbar Valve                                             |                                                          |                  |

- Availability may vary among countries/regions.
- Only available in the USA.
- Natus Medical Incorporated acquired certain neurosurgery business assets including the ASD and GCA from Integra Life Sciences in 2017. Integra LifeSciences acquired Codman Neurosurgery from Johnson & Johnson in the same year.
## Conclusions

ASDs may be used in the management of overdrainage induced by shunting; however, the use of ASDs may hinder the improvement of some functions in patients with iNPH or poor brain compliance. In addition, the implanted level and angle of ASD, the age, physical activity, and BMI of the patients may affect the function of the ASDs that were designed with different mechanisms. There is no ideal ASD, which is as physiologic as IJV. Neurosurgeons should be familiar with the mechanisms and physical characteristics of the implants they use. The indication of placement of an ASD and the type of ASD should be determined according to the patient’s need. The ideal location of the ASD should also be considered carefully according to the patient’s age and the characteristics of the ASDs.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.bj.2021.08.001](https://doi.org/10.1016/j.bj.2021.08.001).

## Acknowledgement

The writing of this article was partly supported by grants from the Ministry of Science and Technology, Taiwan (MOST 109-2314-B-002-124 to Dr. MF Kuo).

## References

1. Hsu CH, Chou SC, Yang SH, Shih MC, Kuo MF. Using a burr hole valve prevents proximal shunt failure in infants and toddlers. J Neurosurg Pediatr 2019 Jun;1:1–8.
2. Decq P, Barat JL, Duplessis E, Leguerinel C, Gendrault P, Keravel Y. Shunt failure in adult hydrocephalus: flow-controlled shunt versus differential pressure shunts—a

### Table 2 Clinical implementation of various antisiphon devices (ASDs) considering different mechanisms of ASD and the condition of patients.

| ASD orientation | Diaphragm | Gravitational | Flow reducing |
|-----------------|-----------|---------------|--------------|
| ASD location of the body | Level of Mastoid | Vertical ± 10°, or posterior inclination | *Retroauricular: growing children |
| *Clavicle/Upper thoracic: for iNPH and poor brain compliance | *Thoracic level: adults |
| *Above mastoid: tend to underdrain |
| ASD encapsulation | Avoid tight pocket | — | *Refer to Supplementary Table 2 |
| ASD setting | — | — | — |

### Patient conditions

| Obese | Y | Y | Y |
| Bedridden | X | X | X |
| Poor consciousness | X | X | X |
| Infant and young children | ∆ | ∆ | ∆ |
| Older children, shorter adults | ∆ | ∆ | ∆ |
| iNPH | ∆ Clavicle/Upper thoracic location | Y | ∆ May not provide sufficient flow in nocturnal ICP elevations |
| Slit ventricle | Y | Y | ∆ |
| Subdural collection | Y | Y | — |

### Patient education

| Sleeping | Avoid lying on the side of the ASD | — | — |
| Exercise | May occasionally lie down (An erect position may prevent any CSF flow) | Rest if discomfort | — |
| Posture | — | Keep the axes of head and body in line if symptoms develop (Discrepancy of the two axes may lead to over- or under-drainage) | — |
| — | — | Avoid semisitting position for too long (Try to stand up or lie down totally to ensure the device switches to the correct state) |

Abbreviations: Doesn’t matter; *, note; iNPH: idiopathic normal pressure hydrocephalus; Y: consider to use; ∆: may consider to use; X: not be used; DP: differential pressure; ICP: intracranial pressure.

* Difficult cases: The setting of gravitational device may need to be adjusted in growing children, those with activity changes, and those who underwent multiple revisions.

## Conflict of interest

All authors declare that they have no competing interests.

## Acknowledgement

The writing of this article was partly supported by grants from the Ministry of Science and Technology, Taiwan (MOST 109-2314-B-002-124 to Dr. MF Kuo).
cooperative study in 289 patients. Surg Neurol 1995;43:333–9.
[3] Pudenz RH, Foltz EL. Hydrocephalus: overdrainage by ventricular shunts. A review and recommendations. Surg Neurol 1991;35:200–12.
[4] Zemack G, Romner B. Adjustable valves in normal-pressure hydrocephalus: a retrospective study of 218 patients. Neurosurgery 2002;51:1392–400. discussion 1400–2.
[5] Kay AD, Fisher AJ, O’Kane C, Richards HK, Pickard JD. A clinical audit of the Hakim programmable valve in patients with complex hydrocephalus. Br J Neurosurg 2000;14:535–42.
[6] Woddworth GF, McGirt MJ, Williams MA, Rigamonti D. Cerebrospinal fluid drainage and dynamics in the diagnosis of normal pressure hydrocephalus. Neurosurgery 2009;64:919–25. discussion 925–6.
[7] Boon AJ, Tans JT, Delwel EJ, Egeler-Peerdeman SM, Hanlo PW, Wurzer HA, et al. Dutch Normal-Pressure Hydrocephalus Study: randomized comparison of low- and medium-pressure shunts. J Neurosurg 1998;88:490–5.
[8] Saehle T, Farahmand D, Eide PK, Tisell M, Wikkelso C. A pragmatic, randomised, open label, multicentre trial (SVASONA). J Neurol Neurosurg Psychiatry 2013;84:850–7.
[9] Drake JM, Kestle JR, Milner R, Cinalli G, Boop F, Piatt Jr J, et al. Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a randomized controlled trial. J Neurosurg 1996;84:634–41.
[10] Holmlund P, Johansson E, Qvarlander S, Wahlin A, Ambarki K, Koskinen LD, et al. Human jugular vein collapse in the upright posture: implications for postural intracranial pressure regulation. Fluids Barriers CNS 2017;14:17.
[11] Miyake H, Ohta T, Kajimoto Y, Nagao K. New concept for the pressure setting of a programmable pressure valve and measurement of in vivo shunt flow performed using a microflowmeter. Technical note. J Neurosurg 2000;92:181–7.
[12] Malm J, Kristensen B, Fagerlund M, Koskinen LO, Ekstedt J. Cerebrospinal fluid shunt dynamics in patients with idiopathic adult hydrocephalus syndrome. J Neurol Neurosurg Psychiatry 1995;58:715–23.
[13] Chatterjee S, Harischandra L. Cerebrospinal fluid shunts - how they work: the basics. Neurol India 2018;66:24–35.
[14] Chapman PH, Cosman ER, Arnold MA. The relationship between ventricular fluid pressure and body position in normal subjects and subjects with shunts: a telemetric study. Neurosurgery 1990;26:181–9.
[15] Martinez-Lage JF, Martos-Tello JM, Ros-de-San Pedro J, Almagro MJ. Severe constipation: an under-recognized cause of VP shunt malfunction: a case-based update. Childs Nerv Syst 2008;24:431–5.
[16] Krauss P, Fritz-Naville M, Regli L, Stieglitz LH. Progressive functional underdrainage in cerebrospinal fluid shunt-dependent women during pregnancy: case report and review of the literature. World Neurosurg 2018;109:372–6.
[17] Depauw FRAM, Groen RJM, Van Loon J, Peul WC, Malbrain MLNG, De Waele JJ. The significance of intra-abdominal pressure in neurosurgery and neurological diseases: a narrative review and a conceptual proposal. Acta Neurochir 2019;161:855–64.
[18] Sahuquillo J, Arikan F, Poca MA, Noguer M, Martinez-Ricarte F. Intra-abdominal pressure: the neglected variable in selecting the ventriculoperitoneal shunt for treating hydrocephalus. Neurosurgery 2008;62:145–9. discussion 149–50.
[19] Cobb WS, Burns JM, Kercher KW, Matthews BD, James Norton H, Todd Heniford B. Normal intraabdominal pressure in healthy adults. J Surg Res 2005;129:231–5.
[20] Marino PL. The ICU Book. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
[21] Portnoy HD, Schulte RR, Fox JL, Croissant PD, Tripp L. Anti-siphon and reversible occlusion valves for shunting in hydrocephalus and preventing post-shunt subdural hematomas. J Neurol 1973;25:729–38.
[22] Hassan M, Higashi S, Yamashita J. Risks in using siphon-reducing devices in adult patients with normal-pressure hydrocephalus: bench test investigations with Delta valves. J Neurosurg 1996;84:634–41.
[23] Gehlen M, Eklund A, Kurtcuoglu V, Malm J, Schmid Daners M. Comparison of anti-siphon devices–how do they affect CSF dynamics in supine and upright posture? Acta Neurochir (Wien) 2017;159:1389–97.
[24] Kurtom KH, Magram G. Siphon regulatory devices: their role in the treatment of hydrocephalus. Neurosurg Focus 2007;22:E5.
[25] Giuseppe Mirone DS, Sainte-Rose Christian. Pediatric Hydrocephalus. 2nd ed. Springer Nature Switzerland AG; 2019.
[26] Tokoro K, Chiba Y. Optimum position for an anti-siphon device in a cerebrospinal fluid shunt system. Neurosurgery 1991;29:519–25.
[27] da Silva MC, Drake JM. Effect of subcutaneous implantation of anti-siphon devices on CSF shunt function. Pediatr Neurosurg 1990;16:197–202.
[40] Horton D, Pollay M. Fluid flow performance of a new siphon-control device for ventricular shunts. J Neurosurg 1990;72:926–32.

[41] Park J, Kim GJ, Hwang SK. Valve inclination influences the performance of gravity-assisted valve. Surg Neurol 2007;68:14–8; discussion 8.

[42] Freimann FB, Luhdo MI, Rohde V, Vajkoczy P, Wolf S, Sprung C. The Frankfurt horizontal plane as a reference for the implantation of gravitational units: a series of 376 adult patients. Acta Neurochir (Wien) 2014;156:1351–6.

[43] Kaestner S, Kruschat T, Nitzsche N, Deinsberger W. Gravitational shunt units may cause under-drainage in bedridden patients. Acta Neurochir (Wien) 2009;151:217–21; discussion 221.

[44] Miethke. ProGAV 2.0: Recommended pressure levels Christoph, https://www.miethke.com/en/products/adjustable-valves/progav-20/; 2021[accessed 29 May 2021].

[45] Gehlen M, Kurtcuoglu V, Daners MS. Patient specific hardware-in-the-loop testing of cerebrospinal fluid shunt systems. IEEE Trans Biomed Eng 2016;63:348–58.

[46] Czosnyka Z, Czosnyka M, Pickard JD. Hydrodynamic performance of a new siphon preventing device: the SiphonGuard. J Neurol Neurosurg Psychiatry 1999;66:408–9.

[47] Czosnyka ZH, Czosnyka M, Richards HK, Pickard JD. Laboratory evaluation of the phoenix CRZ diamond valve. Neurosurgery 2001;48:689–93. discussion 693–4.

[48] Sainte-Rose C, Hooven MD, Hirsch JF. A new approach in the treatment of hydrocephalus. J Neurosurg 1987:66:213–26.

[49] Tschan CA, Antes S, Huthmann A, Vulcu S, Oertel J, Wagner W. Overcoming CSF overloadage with the adjustable gravitational valve proSA. Acta Neurochir (Wien) 2014;156:767–76. discussion 776.

[50] Kehler U, Kiefer M, Eymann R, Wagner W, Tschan CA, Langer N, et al. PROSAIKa: a prospective multicenter registry with the first programmable gravitational device for hydrocephalus shunting. Clin Neurol Neurosurg 2015;137:132–6.

[51] Meling TR, Egge A, Due-Tennessen B. The gravity-assisted paedi-Gav valve in the treatment of pediatric hydrocephalus. Pediatr Neurosurg 2005;41:8–14.

[52] Eymann R, Steudel WI, Kiefer M. Pediatric gravitational shunts: initial results from a prospective study. J Neurosurg 2007;106:179–84.

[53] Hertel F, Züchner M, Decker C, Schill S, Bosniak I, Bettag M. The Miethke dual switch valve: experience in 169 adult patients with different kinds of hydrocephalus: an open field study. Minim Invasive Neurosurg 2008;51:147–53.

[54] Haberi DJ, Messing-Jünger M, Schumann M, Eymann R, Cedzich C, Fritsch MJ, et al. Experience with a gravity-assisted valve in hydrocephalic children. J Neurosurg: Pediatr 2009;4:289–94.

[55] Kiefer M, Eymann R. Gravitational shunt complications after a five-year follow-up. Acta Neurochir Suppl 2010;106:107–12.

[56] Sprung C, Schlosser HG, Lemcke J, Meier U, Messing-Jünger M, Trost HA, et al. The adjustable proGAV shunt: a prospective safety and reliability multicenter study. Neurosurgery 2010;66:465–74.

[57] Weinzierl MR, Hans FJ, Stoffel M, Oertel MF, Korinth MC. Experience with a gravitational valve in the management of symptomatic overdrainage in children with shunts. J Neurosurg Pediatr 2012;9:648–72.

[58] Suchorska B, Kunz M, Schniepe R, Jahn K, Goetz C, Tonn JC, et al. Optimized surgical treatment for normal pressure hydrocephalus: comparison between gravitational and differential pressure valves. Acta Neurochir (Wien) 2015;157:703–9.

[59] Sokrates G, Hadfield O, Van Tonder I, Hennigan D, Ellenbogen J, Pettorini B, et al. Management of paediatric hydrocephalus with Miethke fixed pressure gravitational valves. The Alder Hey Children’s Hospital experience. Childs Nerv Syst 2020;36:2021–5.

[60] Freimann FB, Sprung C. Shunting with gravitational valves—can adjustments end the era of revisions for overdrainage-related events?: clinical article. J Neurosurg 2012;117:1197–204.

[61] Koueik J, Kraemer MR, Hsu D, Rizk E, Zee R, Haldeman C, et al. A 12-year single-center retrospective analysis of antisiphon devices to prevent proximal ventricular shunt obstruction for hydrocephalus. J Neurosurg Pediatr 2019 Sep:1–10.

[62] Alavi S, Schulz M, Schaumann A, Schwarz K, Thomale UW. Valve exchange towards an adjustable differential pressure valve with gravitational unit, clinical outcome of a single-center study. Childs Nerv Syst 2017;33:759–65.

[63] Kondagesi C, Thompson D, Reynolds M, Hayward RD. Experience with the Strata valve in the management of shunt overdrainage. J Neurosurg 2007;106:95–102.

[64] Jain H, Sgouros S, Walsh AR, Hockley AD. The treatment of infantile hydrocephalus: “differential-pressure” or “flow-control” valves. A pilot study. Childs Nerv Syst 2000;16:242–6.

[65] Davis SE, Levy ML, McComb JG, Sposto R. The Delta valve: how does its clinical performance compare with two other pressure differential valves without antisiphon control? Pediatr Neurosurg 2000;33:58–63.

[66] Virella AA, Galarza M, Masterman-Smith M, Lemus R, Lazareff JA. Distal slit valve and clinically relevant CSF overdrainage in children with hydrocephalus. Childs Nerv Syst 2002;18:15–8.

[67] Desai VR, Sadrameh SS, Jenson AV, Asante SK, Daniels B, Trask TW, et al. Ventriculoperitoneal shunt complications in an adult population: a comparison of various shunt designs to prevent overdrainage. Surg Neurol Int 2020;11:269.

[68] Di Rocco C. Is the slit ventricle syndrome always a slit ventricle syndrome? Childs Nerv Syst 1994;10:49–58.

[69] Gruber RW, Roehrig B. Prevention of ventricular catheter obstruction and slit ventricle syndrome by the prophylactic use of the Integra antisiphon device in shunt therapy for pediatric hypertensive hydrocephalus: a 25-year follow-up study. J Neurosurg Pediatr 2010;5:4–16.

[70] McGirt MJ, Leveque JC, Wellons 3rd JC, Villavicencio AT, Hopkins JS, Fuchs HE, et al. Cerebrospinal fluid shunt survival and etiology of failures: a seven-year institutional experience. Pediatr Neurosurg 2002;36:248–55.

[71] Hauptman JS, Kestle J, Riva-Cambrin J, Kulkarni AV, Browd SR, Rozzell CJ, et al. Predictors of fast and ultrafast shunt failure in pediatric hydrocephalus: a 25-year institutional study. J Neurosurg Pediatr 2010;5:4–16.

[72] Shah SS, Hall M, Slonim AD, Hornig GW, Berry JG, Sharma V. A multicenter study of factors influencing cerebrospinal fluid shunt survival in infants and children. Neurosurgery 2008;62:1095–102. discussion 1102–3.

[73] Tuli S, Drake J, Lawless J, Wigg M, Lamberti-Pasculli M. Risk factors for repeated cerebrospinal fluid shunt failures in pediatric patients with hydrocephalus. J Neurosurg 2000;92:31–8.

[74] Gebert AF, Schulz M, Schwarz K, Thomale UW. Long-term survival rates of gravity-assisted, adjustable differential pressure valves in infants with hydrocephalus. J Neurosurg Pediatr 2016;17:544–51.

[75] Thomale UW, Gebert AF, Haberi H, Schulz M. Shunt survival rates by using the adjustable differential pressure valve combined with a gravitational unit (proGAV) in pediatric neurosurgery. Childs Nerv Syst 2013;29:425–31.
Kestle J, Drake J, Milner R, Sainte-Rose C, Cinalli G, Boop F, et al. Long-term follow-up data from the shunt design trial. Pediatr Neurosurg 2000;33:230–6.

Kestle JR, Walker ML. A multicenter prospective cohort study of the Strata valve for the management of hydrocephalus in pediatric patients. J Neurosurg 2005;102:141–5.

Ahn ES, Bookland M, Carson BS, Weingart JD, Jallo GI. The Strata programmable valve for shunt-dependent hydrocephalus: the pediatric experience at a single institution. Childs Nerv Syst 2007;23:297–303.

Hanlo PW, Cinalli G, Vandertop WP, Faber JA, Bøgesen L, Børgesen SE, et al. Treatment of hydrocephalus determined by the European Orbis Sigma Valve II survey: a multicenter prospective 5-year shunt survival study in children and adults in whom a flow-regulating shunt was used. J Neurosurg 2003;99:52–7.

Beuriat PA, Puget S, Cinalli G, Blauwblomme T, Beccaria K, Zerah M, et al. Hydrocephalus treatment in children: long-term outcome in 975 consecutive patients. J Neurosurg Pediatr 2017;20:10–8.

Kaiser GL, Horner E, Marchand S, Jost A. Conventional versus Delta valve in the treatment of hydrocephalus in early infancy. Eur J Pediatr Surg 1997;7Suppl 1:45–6.

Kraemer MR, Sandoval-Garcia C, Bragg T, Iskandar BJ. Shunt-dependent hydrocephalus: management style among members of the American Society of Pediatric Neurosurgeons. J Neurosurg: Pediatr PED 2017;20:216–24.

Aschoff A, Kremer P, Benesch C, Fruh K, Klank A, Kunze S. Overdrainage and shunt technology. A critical comparison of programmable, hydrostatic and variable-resistance valves and flow-reducing devices. Childs Nerv Syst 1995;11:193–202.

McCullough DC. Symptomatic progressive ventriculomegaly in hydrocephalics with patent shunts and antisiphon devices. Neurosurgery 1986;19:617–21.

Bergsneider M, Peacock WJ, Mazziotta JC, Becker DP. Beneficial effect of siphoning in treatment of adult hydrocephalus. Arch Neurol 1999;56:1224–9.

Bergsneider M, Black PM, Klinge P, Marmarou A, Relkin N. Surgical management of idiopathic normal-pressure hydrocephalus. Neurosurgery 2005;57:S29–39. discussion ii-v.

Freimann FB, Vajkoczy P, Sprung C. Patients benefit from low-pressure settings enabled by gravitational valves in normal pressure hydrocephalus. Clin Neurol Neurosurg 2013;115:1982–6.

Bozhkov Y, Roessler K, Hore N, Buchfelder M, Brandner S. Neurological outcome and frequency of overdrainage in normal pressure hydrocephalus directly correlates with implanted ventriculo-peritoneal shunt valve type. Neurol Res 2017;39:601–5.

Sahuquillo J, Rosas K, Calvo H, Alcina A, Gándara D, López-Bermeo D, et al. How to choose a shunt for patients with normal pressure hydrocephalus: a short guide to selecting the best shunt assembly. J Clin Med 2021;10:1210.

Hakim S. Hydraulic and mechanical mis-matching of valve shunts used in the treatment of hydrocephalus: the need for a servo-valve shunt. Dev Med Child Neurol 1973;15:646–53.